The comparative OS results in subgroups by geographic region (Asia or ROW) and by primary tumor location (i.e., stomach or GEJ) were consistent with the base case, demonstrating that the three anti-PD-1 regimens were similarly efficacious in patients with GC/GEJC irrespective of these factors. This evidence concerns the gene PDCD1 and gastric cancer.